Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
American Journal of Hematology|October 15, 2013
Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemiaMoshe C Ornstein, Sudipto Mukherjee, Sanjay Mohan, et al.
Blood|May 10, 2011
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres, Holly Gundacker, Jeffrey Lancet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology GuidelineValérie de Haas, Nofisat Ismaila, Anjali Advani, et al.
Seminars in Oncology|February 1, 2012
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah, Pierre Triozzi, Brian Rini, et al.
Scientific Reports|April 7, 2022
AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarkerDeepti Reddi, Brandon W Seaton, David Woolston, et al.
Leukemia & Lymphoma|January 8, 2015
Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapyMoshe C Ornstein, Sudipto Mukherjee, Michael Keng, et al.
American Journal of Hematology|April 4, 2017
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemiaHagop M Kantarjian, Michael W Schuster, Nitin Jain, et al.
Haematologica|May 25, 2011
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemiaManuel G Afable, Mohammed Shaik, Yuka Sugimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, James S Blachly, Armin Ghobadi, et al.
Pageof 6